Purdue Pharma L.p.

Euro-celtique S.a.

Harm Reduction Therapeutics, Inc.

Rhodes Pharmaceuticals L.p.

Alexander Oksche

Derek Allan Prater

Malcolm Walden

Richard S Sackler

Kevin John Smith

Timothy Holden

William Heath

Stephen Harris

John Strang

Lucie Helene Jeanne Mottier

Hassan Mohammad

John Watkins

Karen Reimer

Yvonne Von Coburg

Heikki Mansikka

Peter Holzer

Paul Bailey

Kevin Smith

Will Heath

Bernard Kennedy

Vanessa Addison

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

Intranasal pharmaceutical dosage forms comprising naloxone

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to &#x2265;0.5 mg naloxone HCl dissolved in an application fluid of a volume of &#x2264;250 &#x3bc;l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to &#x2265;0.5 mg naloxone HC dissolved in an application fluid of a volume of &#x2264;250 &#x3bc;l. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.

The present invention provides a method of providing pain relief in a human subject in need thereof comprising administering (R)-dihydroetorphine to said subject, wherein said (R)-dihydroetorphine is administered in a dose of at least 0.01 &#x3bc;g/kg, preferably at least 0.05 &#x3bc;g/kg, and the level of respiratory depression in said subject is 65 or less % relative to the baseline level pre-administration of (R)-dihydroetorphine.

Dihydroetorphine for the provision of pain relief and anaesthesia

The present invention is concerned with an oral pharmaceutical dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain in patients suffering from i) pain and at least one further disease ii), wherein said at least one further disease ii) results in intestinal dysbiosis, or for use in the treatment of pain in patients suffering from i) pain and at least one further disease iii), wherein said at least one further disease iii) increases the risk for intestinal bacterial translocation and thus for peritonitis, SIRS and/or sepsis.

Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug substitution therapy in drug-dependent human subjects.

Buprenorphine-wafer for drug substitution therapy

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Opioid composition for treating skin lesions

Growing community of inventors

Limburg, Germany

Alexander Oksche